Clinical Trial Update: Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating intravenous Acetadote (N-acetylcysteine) for prevention of contrast-induced nephropathy. The update does not provide current results or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy

Drugs mentioned

• ACETADOTE (Acetylcysteine)

Snippet

Sponsor: Ochsner Health System | Conditions: Nephropathy | Phase 4 | Status: UNKNOWN